US4764515A
Expired / Lapsed
US
⏱️ 0.0 years remaining
Antitussive and central sedative composition of d-isomer of 3-(4-phenyl-1-piperazinyl)-1,2-propanediol
Assignee: Dompe Farmaceutici SpA
•
Filing: 1987-07-02
•
Granted: 1988-08-16
•
Expires: 2007-07-02
Abstract
Abstract The optical isomers of 3-(4-phenyl-1-piperazinyl)-1,2-propanediol, a process for the stereo-selective preparation and pharmaceutical composition containing the same as active principles are described.
Inventors
- 👤 Massimiliano Borsa
- 👤 Giancarlo Tonon
- 👤 Salvatore Malandrino
Bibliographic Details
Application Number
—
Jurisdiction
US
Data Source
google_patents
Last Synchronized
2026-10-30 04:10
CPC Classifications
C; C07; C07D; C07D295/00; C07D295/04; C07D295/08; C07D295/084; C07D295/088; A; A61; A61P; A61P11/00; A61P11/14; A61P25/00; A61P25/20; A61P29/00; C07C; C07C309/00; C07D317/00; C07D317/08; C07D317/10; C07D317/14; C07D317/18; C07D317/20; C07D317/22; C07D317/32
Claims Analysis
Total Claims: 3
Claim 1
Independent Claim
65 words
A pharmaceutical composition having central sedative activity consisting essentially of an effective amount of the d-isomer of 3-(4-phenyl-1-piperazinyl)-1,2-propanediol isolated from a racemic mixture of the l- and d-isomers, together with a pharmaceutically acceptable carrier, said composition exhibiting, when administered to a patient, an essentially equivalent central sedative activity but a substantially lower antitussive activity, than a composition containing a like amount of the racemic mixture.
Claim 2
Dependent Claim
65 words
A pharmaceutical composition having central sedative activity consisting essentially of an effective amount of the d-isomer of 3-(4-phenyl-1-piperazinyl)-1,2-propanediol isolated from a racemic mixture of the l- and d-isomers, together with a pharmaceutically acceptable carrier, said composition exhibiting, when administered to a patient, an essentially equivalent central sedative activity but a substantially lower antitussive activity, than a composition containing a like amount of the racemic mixture.
Claim 3
Dependent Claim
26 words
A method of administering a mild central sedative to a patient which comprises orally introducing an effective dosage of the pharmaceutical composition according to claim 1.
References Cited (Backward Citations)
No citation records indexed.
USPTO Annuity & Maintenance Windows
| Annuity Stage | Window Opens | Payment Deadline | Surcharge Period Until | Estimated Fee | Status |
|---|---|---|---|---|---|
| 3.5 Years (Year 4) | 1991-08-16 | 1992-02-15 | 1992-08-16 | $2000.00 | Window Closed / Lapsed |
| 7.5 Years (Year 8) | 1995-08-16 | 1996-02-15 | 1996-08-16 | $3760.00 | Window Closed / Lapsed |
| 11.5 Years (Year 12) | 1999-08-16 | 2000-02-15 | 2000-08-16 | $7700.00 | Window Closed / Lapsed |